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Abstract 
Lentiviral vector genomic RNA requires sequences that partially overlap wild-type HIV-1 gag 
and env genes for packaging into vector particles. These HIV-1 packaging sequences constitute 
19.6% of the wild-type HIV-1 genome and contain functional cis elements that potentially 
compromise clinical safety. Here, we describe the development of a novel lentiviral vector 
(LTR1) with a unique genomic structure designed to prevent transfer of HIV-1 packaging 
sequences to patient cells, thus reducing the total HIV-1 content to just 4.8% of the wild-type 
genome. This has been achieved by reconfiguring the vector to mediate reverse-transcription 
with a single strand transfer, instead of the usual two, and in which HIV-1 packaging sequences 
are not copied. We show that LTR1 vectors offer improved safety in their resistance to 
remobilisation in HIV-1 particles and reduced frequency of splicing into human genes. 
Following intravenous luciferase vector administration to neonatal mice, LTR1 sustained a 
higher level of liver transgene expression than an equivalent dose of a standard lentivirus. LTR1 
vectors produce reverse-transcription products earlier and start to express transgenes 
significantly quicker than standard lentiviruses after transduction. Finally, we show that LTR1 is 
an effective lentiviral gene therapy vector as demonstrated by correction of a mouse haemophilia 
B model. 
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Introduction 
The Retroviridae family of viruses were first investigated as vectors for mammalian gene 
transfer over 30 years ago and this technology continues to develop 1,2. The current generations 
of lentiviral vectors are based on human immunodeficiency virus type 1 (HIV-1) 3–6 in which the 
vector RNA must contain a significant portion of the wild-type HIV-1 genome to enable 
successful packaging into virus particles. 
The HIV-1 elements that must be present in lentiviral vectors include the RNA packaging signal 
(Ψ), the major splice donor and the Rev-response element (RRE), which are implicated in vector 
RNA processing and packaging into viral particles 7–10. During viral particle assembly the 
nucleocapsid protein recognises and binds to Ψ to ensure that RNA is encapsidated by the 
budding virion 11,12. The RRE interacts with the HIV-1 Rev protein to stabilize transcripts and 
promote RNA export from the nucleus 13–18. 
Following transduction of target cells, the RNA genome in a standard lentiviral vector is reverse-
transcribed to form a double-stranded DNA provirus. The HIV-1 long terminal repeats (LTRs) 
mark the boundaries of the reverse transcribed template, thus Ψ and RRE are always 
incorporated into standard lentiviral vector proviruses and integrated into the host cell genome as 
they are situated between the LTRs. 
The persistence of HIV-1-derived elements in target cells presents a risk for clinical translation 
of lentiviral technology due to potential interactions between virus and patient genomes. The Ψ 
and RRE portions of lentiviral vector DNA contain functional cis elements, such as the major 
splice donor, that can disrupt cellular processes in patient cells. For example, it has been shown 
that integrated lentiviral proviruses can up-regulate the human growth hormone receptor due to 
interactions between the HIV-1 major splice donor and splice acceptors in the human growth 
hormone receptor gene 19. Additionally, it has been observed that splice acceptors in lentiviral 
vector packaging sequences can splice with patient genes to create aberrant fusion transcripts 20. 
This was recently observed in a gene therapy clinical trial for β-thalassaemia in which splicing 
between the patient HMGA2 gene and an integrated lentiviral provirus caused dysregulation of 
HMGA2 transcription and a large clonal expansion of a transduced cell 21. The presence of the Ψ 
packaging element in vector proviruses presents further problems by enabling remobilisation of 
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proviral transcripts in HIV-1-infected cells 22–24. Provirus remobilisation in HIV-1 infected 
patients has been cited as a primary safety concern in the clinical use of lentiviral vectors 25,26. If 
standard lentiviruses were used in HIV-positive patients there is a possible risk of lentiviral 
vector proviruses being remobilised by HIV factors supplied in trans and for potential 
recombination events with wild-type HIV-1 genomes. Furthermore, any transgene cassette 
remobilised in HIV-1 particles could be transferred to any newly infected individuals. 
Previous attempts to remove Ψ and RRE from lentiviral vector proviruses have been largely 
unsuccessful. Cui et al. attempted to further truncate the Ψ and RRE sequences in the lentiviral 
vector genome in efforts to minimise the transfer of HIV-1 DNA 27. This resulted in aberrant 
splicing of the vector genome in HEK293T producer cells and functional vector propagation was 
found to be dependent on the use of an unconventional TE671 rhabdomyosarcoma producer cell 
line. Delviks et al. attempted to exploit homologous recombination events that occur during viral 
reverse-transcription to ‘skip’ the vector packaging signal during provirus synthesis, although 
this technique operated with limited efficiency as skipping did not always occur 28. More 
recently, Cre-loxP mediated deletion of the Ψ and RRE sequences was used to markedly reduce 
the prevalence of these sequences in transduced cells, although again the level of efficiency was 
limited by the efficiency of recombination and Cre expression in target cells may be undesirable 
or unfeasible in clinical applications 29. These investigations exemplify the technical challenges 
that complicate the removal of HIV-1 packaging sequences from clinical-grade vectors. 
Here we describe the development and initial application of a novel lentiviral vector, LTR1, in 
which the HIV-1 packaging sequences have been relocated to avoid their transfer into target cell 
nuclei. In LTR1 vector RNA, the HIV-1 Ψ and RRE packaging sequences are located 
downstream of a single self-inactivating LTR (sin.LTR) 5. This positioning ensures that the 
necessary HIV-1 structures are present for efficient RNA packaging and processing in producer 
cells, but absent from the delivered provirus due to their exclusion from reverse-transcription. As 
a result, LTR1 proviruses contain just 441bp of the wild-type HIV-1 genome, which is limited to 
the vector LTRs, primer binding site and polypurine tracts. We have iteratively optimised the 
structure of LTR1 to achieve high titres for in vivo gene therapy applications and we have 
investigated LTR1 gene transfer both in vitro and in vivo to compare this system to standard 
lentiviral technology. 
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Results 
Optimisation of LTR1 genome to achieve vector titres sufficient for gene therapy 
The premise of LTR1 technology is to generate an RNA genome that mimics the first strand that 
is synthesised during the initial stages of reverse-transcription in target cells (known as the 
‘minus strand’). This is achieved in LTR1 vectors by removing the vector 5’LTR, thus leaving 
the HIV-1 primer binding site (PBS) at the extreme 5’ terminus of the vector RNA. An 
additional PBS is situated immediately downstream of a solitary self-inactivating LTR (ΔU3 
SIN) 5, followed by the necessary packaging sequences. The location of PBS immediately 
downstream of the LTR ensures the necessary proximity of the upstream primer activation 
signal, which is present within the LTR U5 region, thus guaranteeing efficient initiation of 
reverse-transcription 30,31. The LTR1 design means that reverse-transcription moves from two 
essential strand transfer events to just one, thus shortening the virus life-cycle. A schematic for 
the expected mechanism of LTR1 reverse-transcription is detailed in Supplementary Figure S1 
and the expected RNA and DNA products are displayed in Figure 1. 
During iterative LTR1 development, vector transduction efficiency was determined by flow 
cytometry, by delivering enhanced green fluorescent protein (GFP) and the woodchuck-hepatitis 
virus post-transcriptional regulatory element (WPRE), driven by either the human 
phosphoglycerate kinase (PGK) promoter, or human Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) promoter. The first iteration of LTR1 was produced by editing a 3rd 
generation pRRL-PGK-eGFP-WPRE lentiviral plasmid (RRL-PEW) 4, for which the PBS and 
Ψ-RRE packaging sequences were moved to a new location between the 3’sin.LTR and early 
Simian Virus 40 polyadenylation sequence (SV40 polyA) (Figure 2a). This vector, termed 
LTR1.0-PGK-eGFP-WPRE (LTR.1.0-PEW), gave an infectious, eGFP titre of 1.2 x 105 
transducing units per milliliter (TU/ml) following concentration by ultracentrifugation, almost 3 
orders of magnitude lower than the standard RRL-PEW vector (3.4 x 108 TU/ml; data not 
shown), as determined by flow cytometric quantification of eGFP expression in transduced 293T 
cells (Figure 2b). 
To increase LTR1 titres to a level suitable for gene therapy applications, the LTR1 genomic 
structure was progressively optimised with the goal of obtaining yields similar to the original 3rd 
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generation lentivirus from which LTR1 was developed (Figure 2a). Two major bottlenecks to 
producing high titre vector were believed to be insufficient nuclear export of vector RNA and 
undesirable transcription termination in the 3’sin.LTR. The majority of the optimisation steps 
were designed to tackle these restrictions. The initial modifications that improved vector titres 
included exchanging the SV40 early polyA for the SV40 late polyA for improved 
polyadenylation (LTR1.5-PEW), use of the cytomegalovirus (CMV) promoter to increase 
expression of vector genomic RNA in producer cells (LTR1.7.671-GEW), and insertion of a 
small chimeric intron into the vector 5’ untranslated region with the intention of increasing 
nuclear export (LTR1.20-GEW) 32. The GAPDH promoter was introduced during development 
of LTR1.7.671-GEW as we observed patchy eGFP fluorescence in producer cells when using the 
PGK promoter (data not shown). 
Full-length LTR1 and CCL vector RNA would be expected to produce a 4kb transcript, when all 
packaging elements are incorporated. However, northern blotting of vector RNA derived from 
LTR1.7.671 and LTR1.20 producer cells showed a strong band at approximately 1.7kb when 3rd 
generation packaging plasmids (without Tat expression) were used, whilst the wild-type CCL-
GEW sample gave the expected 4kb band at a greater frequency (Supplementary Figure S2). Co-
transfection with pcDNA3.Tat during vector production was able to rescue the 4kb band in 
northern blotted LTR1.7.671-GEW and LTR1.20-GEW genomic RNA, indicating that efficient 
processing of LTR1 vector RNA during vector production is relatively dependent on the 
presence of HIV-1 Tat in producer cells. For this reason, Tat was included during the production 
of all LTR1 and CCL vectors for the remainder of the experiments. 
The close proximity of the CMV enhancer to the internal GAPDH promoter in pLTR1.20-GEW 
and pLTR1.7.671-GEW may have strengthened the activity of this internal GAPDH promoter in 
producer cells, thus resulting in some vector transcripts being initiated from the GAPDH 
promoter itself (rather than CMV) and consequentially missing important upstream elements 
(PBS, cPPT). To combat potential CMV enhancement of the internal GAPDH promoter, we 
introduced larger introns in the 5’ untranslated region to effectively add space between the two 
promoters. Insertion of a truncated β-globin intron (LTR1.25-GEW) or an elongation factor 1 α 
intron (LTR1.27-GEW) was successful in increasing the functional titre (P = 0.004 by Kruskal-
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Wallis comparison of all vector titres) (Figure 2b). At this stage, LTR1.27 titres can be produced 
with efficiency equivalent to approximately 35% of a standard lentiviral vector (pCCL) titre. 
LTR1 proviruses are devoid of HIV-1 packaging sequences 
The absence of HIV-1 packaging sequences from the delivered provirus is fundamental to the 
benefits of LTR1 technology. To confirm that the packaging signal is not copied during reverse 
transcription, two methods were used to sequence LTR1-derived DNA proviruses in transduced 
cell lines. 
Initially, a polymerase chain reaction (PCR) was carried out using genomic DNA harvested from 
HT1080 cells transduced with an LTR1.20 vector containing eGFP expressed by the spleen 
focus-forming virus promoter (SFFV) (LTR1.20-SFFV-eGFP). The PCR was designed to 
amplify the region spanning from the 5’LTR-PBS junction up to the R component of the 3’LTR. 
Resolution of the PCR product by agarose gel electrophoresis showed that LTR1.20 products 
were approximately 2.4kb, which matched the expected size of products lacking HIV-1 
packaging sequences (Supplementary Figure S3). This confirmed that LTR1.20-SFFV-eGFP 
products are indeed smaller than those derived from CCL-SFFV-eGFP, with an estimated 
provirus size difference of 1.3kb. The sequence composition of the PCR products was confirmed 
by Sanger sequencing, which matched the expected provirus structures (data not shown). 
A ‘plasmid rescue’ method 33 was also implemented to confirm the structure of LTR1 product by 
enabling  recovery and direct sequencing of integrated proviruses from transduced HEK 293T 
cells. In this process, the pBR322 bacterial origin of replication and selection marker were 
relocated to the transgene region of the pLTR1.20 plasmid to allow propagation of the provirus 
products in competent bacteria, following provirus recovery from transduced mammalian cells 
(Supplementary Figure S4). Sequencing of LTR1.20-rescue proviruses confirmed that the 
expected provirus structure, with Ψ and RRE removed, was present in transduced cells and these 
products had successfully integrated into the cell genome with expected dinucleotide repeats 
(Supplementary Figure S5). 
LTR1 transduction characteristics compared to 3rd generation CCL in vitro 
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In vitro experiments were carried out to further characterise LTR1 vectors and compare them to 
a 3rd generation lentiviral vector. For these investigations, we used vectors containing an SFFV-
driven bicistronic luciferase-eGFP reporter gene in which luciferase and eGFP are separated by a 
T2A cleavage peptide (SFFV-Luc-T2A-eGFP) 34. HT1080 cells were transduced with a range of 
LTR1.20-SFFV-Luc-T2A-eGFP or CCL-SFFV-Luc-T2A-eGFP doses. Two weeks after 
transduction, eGFP expression was analysed by flow cytometry and vector copy numbers were 
quantified by qPCR titration of the genomic DNA. Lentiviral titres were determined by p24 
ELISA (lp/ml), qRT-PCR of packaged single-stranded RNA genomes (ssRNAvg/ml), qPCR 
analysis of integrated double-stranded DNA vector genome proviruses (dsDNAvg/ml) and flow 
cytometric quantification of eGFP-positive cells (TU/ml) (Table 1). 
The data in Table 1 show that, while LTR1.20-GEW particle and RNA genome titres are similar 
to CCL, the provirus titre and eGFP titre appear to be restricted. We further analysed these 
parameters by calculating the approximate efficiency of key steps in the viral life cycle. The 
relative packaging efficiency was calculated by expressing the RNA titre as a percentage of the 
particle titre, whilst the transgene expression efficiency was based on the eGFP titre as a 
percentage of the provirus titre. The efficiency of LTR1 packaging (86.3%) and transgene 
expression (59.0%) was similar to CCL (80.2% and 72.8%). Reverse-transcription efficiency 
was calculated by expressing the provirus titre as a percentage of the RNA genome titre. This 
value showed that LTR1.20 (0.16%) was less efficient than CCL (33.04%) at converting its RNA 
genome into a stable provirus. 
The similarities and differences between LTR1.20 and CCL vector parameters are shown in 
more detail in Figure 3. Plotting the integrated vector copy number (VCN) versus the mean 
fluorescence intensity (MFI) of eGFP expression (Figure 3a) shows that transgene expression 
efficiency per LTR1.20 provirus matches the level derived from the CCL vector. However, when 
plotting the p24 and RNA genome doses versus the percentage of GFP-positive cells (Figure 3b 
and Figure 3c), it becomes apparent that LTR1.20 requires a greater total particle number and 
RNA dose than CCL to achieve an equivalent effect, underlining the potential inefficiency 
during transduction. 
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LTR1 proviruses are resistant to remobilisation in the presence of HIV-1 packaging 
components provided in trans 
Despite self-inactivating lentiviruses lacking an active promoter in the 5’LTR 5, it has been 
reported that lentivirus-transduced cells can still produce full-length RNA genomes that are 
remobilised in new virions when host cells are actively producing HIV-1 components 22,23. 
Possible remobilisation of gene therapy vectors in patients infected with HIV presents significant 
safety and regulatory concerns 25,26. We hypothesised that the absence of HIV-1 packaging 
sequences from LTR1 proviruses would confer resistance to re-packaging of any full-length 
RNA in target cells where HIV-1-based packaging components were provided in trans. 
To investigate this, we transduced HEK 293T cells with a 2-fold dilution series of LTR1.20-
SFFV-eGFP or CCL-SFFV-eGFP and maintained the populations in culture for 11 days. 
Genomic DNA was harvested from each transduced population for VCN quantification and the 
remaining cells were plated out and transfected with lentiviral packaging plasmids to create a 
pool of mock-HIV-1-infected cells. Vector supernatants were subsequently harvested and 
purified prior to addition to HT1080 cells, which were analysed at 10 days post-transduction to 
quantify any expression from functional vector particles with the ability to deliver stably 
integrated remobilised viral genomes (Figure 4). 
LTR1.20 samples were completely devoid of any remobilised proviruses, revealed by the lack of 
eGFP expression at all VCN doses. 3rd generation lentivirus (CCL) samples were positive for 
eGFP expression, with remobilised titres calculated in the range of 5.9 x 102 – 1.5 x 104 TU/ml, 
where area under the curve (AUC) increased in correlation with the starting vector copy number 
(P = 0.0004 by t-test) (Figure 4a). 
Three example flow cytometry dot plots show clear eGFP-positive colonies produced by a CCL-
derived vector (Supplementary figure S6) remobilised from a HEK 293T population possessing a 
CCL vector copy number of 2.03 vector genomes per cell. LTR1.20 was not remobilised from 
HEK 293T cells containing 3.75 genomes per cell, with plots indistinguishable from a non-
transduced negative controls. 
The risk of generating vector host-fusion transcripts is reduced with LTR1 technology 
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Transcripts derived from lentiviral vector proviruses have been shown to fuse with neighbouring 
gene transcripts in patient cells through splicing interactions between HIV-1 splice sites and the 
human genome 19–21. This constitutes a safety risk for clinical gene therapy. We hypothesised 
that the absence of HIV-1 major splice donor and Ψ-RRE splice acceptors from LTR1 vector 
proviruses would influence the frequency of vector-host fusion transcripts, so we performed a 
basic analysis of cellular fusion transcripts. 
HEK 293T cells were transduced with CCL-GEW, LTR1.7.671-GEW, or LTR1.20-GEW at a 
range of doses and expanded for 14 days to deplete any unintegrated proviruses. Vector copy 
numbers were calculated by qPCR (3.43 for CCL, 2.82 for LTR1.7.671 and 3.62 for LTR1.20). 
Total RNA was extracted from transduced cells and ribosomal RNA was depleted prior to 
preparation of next-generation sequencing libraries. Sequencing reads were analysed for fusion 
transcripts by mapping paired reads to the human genome and subsequently to the relevant 
vector provirus, to find the frequency of human-vector transcript chimera per human genomic 
transcript. The number of fusion transcripts per 106 human transcripts was then normalized to the 
dsDNA provirus copy number in each sample. 
The fusion transcript frequency detected in CCL samples (0.54±0.06) was significantly greater 
than LTR1.7.671 samples (0.07±0.02) and LTR1.20 samples (0.14±0.02) (P = 0.027 by Kruskal-
Wallis test) (Figure 4b). These values were also expressed relative to the number of CCL fusion 
transcripts, to highlight the reduced frequency of splice fusions when using LTR1.7.671 
(12.97±5.64 % of CCL level) and LTR1.20 (26.5±0.86 % of CCL level) (P = 0.024 by Kruskal-
Wallis test) (Figure 4c). 
LTR1 vectors can exceed standard lentiviral vector efficacy in the liver following murine 
neonatal intravenous injection of titre-matched viruses 
To confirm that expression from an LTR1 provirus was detectable in vivo, LTR1.20-SFFV-eGFP 
(titre 2.34 x 107 TU/ml) was produced and administered intracranially or intravenously to 
newborn CD1 mice (Figure 5). Examination of eGFP expression 1 week after vector 
administration demonstrated that LTR1 could efficiently deliver transgene expression to mouse 
liver and brain (Figure 5a). Immunostaining of dissected brains demonstrated that stable eGFP 
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expression existed predominantly within the cortex and hippocampus of the injected hemisphere 
(Figure 5b). 
To compare longitudinal LTR1-driven in vivo expression to a CCL vector, the SFFV-Luc-T2A-
eGFP bicistronic construct was used to allow bioluminescence imaging. Equivalent volumes of 
lentiviral vectors (LTR1.20 titre of 2.0 x 107 TU/ml; CCL titre of 3.6 x 107 TU/ml) were 
administered either intracranially or intravenously to newborn CD1 mice, which were then 
monitored for 36 days. 
In vivo LTR1.20-SFFV-Luc-T2A-eGFP bioluminescence imaging revealed that the brain 
expression profiles of LTR1.20 did not show a statistically significant difference to CCL vectors 
(P = 0.087) (Figure 5c). However, comparison of luciferase expression in the livers of 
intravenously injected animals showed a significantly higher bioluminescent output from LTR1 
vectors over the 36 day period (P = 0.018) (Figure 5d). The biodistribution and intensity of 
luciferase expression is shown in representative images at 0, 5, 15 and 36 days post-
administration in Supplementary Figure S7. 
The onset of transgene expression from LTR1 vectors occurs earlier than 3rd generation 
lentiviral vectors 
An interesting observation was made when imaging the SFFV-Luc-T2A-eGFP animals 
immediately after vector administration. At just 20 minutes post-injection, luciferase expression 
was detectable in all LTR1.20-treated animals, but not in animals injected with 3rd generation 
CCL vectors (Figure 6a). 
In light of this finding, we sought to profile the timing of LTR1-derived expression during the 
initial stages after transduction. HT1080 cells were transduced at a multiplicity of infection 
(MOI) of 1 with LTR1.11.1-GEW, LTR1.13.0-GEW, or CCL-GEW (vector schematics can be 
found in Figure 2a). Flow cytometric analysis during the initial 48 hours after transduction 
revealed that the percentage of eGFP-positive cells derived from the LTR1.13.0 backbone was 
already at 8% just 1 hour after transduction, increasing at each subsequent time-point (Figure 
6b). Expression from the LTR1.11.1 and CCL backbones, which each contain a 5’LTR in their 
leader sequence, was minimal until 8 hours after transduction and increased thereafter. The 
percentage of eGFP-positive cells produced by LTR1.13.0 was significantly higher than 
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LTR1.11.1 and CCL over the duration of the experiment, as determined by the differences 
between area under the curves (P = 0.039 by Kruskal-Wallis multi-comparison test). 
We looked deeper into the rapid onset of LTR1 expression by examining the timing of 
intracellular reverse-transcription products, by Late-RT qPCR 35 (Figure 6c). This analysis 
revealed that LTR1.13.0 reverse-transcription products were significantly greater than CCL over 
the initial 6 hours post-transduction (P = 0.036 by t-test). LTR1.13.0 Late-RT products were 
detectable by 1 hour post-injection, at a level not matched by CCL until 4 hours post-injection 
(Figure 6c). LTR1.11.1 did not produce Late-RT products significantly faster than CCL (P = 
0.057), suggesting that minus-strand transfer may be an influential factor in the onset of LTR1 
expression. 
LTR1 vectors can be used to correct a Factor-IX deficient mouse model 
To demonstrate gene therapy with LTR1 technology, we sought to correct a Factor IX-deficient 
mouse model of haemophilia B by in vivo Factor IX gene transfer. For this, we used codon-
optimised factor IX cDNA (FIX) containing the hyperactive Padua mutation 36. To provide 
sufficient vector yields for this experiment LTR1.25 and LTR1.27 backbones were used 
alongside the conventional CCL vector backbone for comparison of in vivo transduction. CCL-
SFFV-FIX, LTR1.25-SFFV-FIX and LTR1.27-SFFV-FIX vectors were titred by qPCR to 
determine the infectious dsDNA proviral copy number. 
Vectors were delivered to neonatal mice by intravenous administration at postnatal day 1. The 
vector doses were determined by the total number of administered viral genomes, with doses 
being 1.4 x 108 dsDNAvg for CCL, 1.7 x 107 dsDNAvg for LTR1.25 and 1.5 x 108 dsDNAvg for 
LTR1.27. Mouse livers and plasma samples were collected upon termination of the experiment. 
The liver proviral copy number was determined by qPCR, which were calculated as being 
1.8±0.9 for LTR1.25 and 1.7±0.9 for LTR1.27 and 1.4±0.5 for CCL (Figure 7a). 
LTR1.25-treated mouse plasma contained mean Factor IX protein levels of 12.2±5.2% of normal 
reference levels, which was similar to the 12.3±3.7% produced by CCL (Figure 7b). Mean 
plasma Factor IX activity was raised to 14.9±7.5% normal levels by LTR1.25, which again 
matched the CCL mean output of 12.6±4.0% (Figure 7c). LTR1.27 treatment gave 22.9±1.7% 
Factor IX protein levels and 24.4±3.0% Factor IX activity. No statistically significant difference 
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was detected during analysis of plasma Factor IX protein (P = 0.153 by Kruskal-Wallis) and 
activity (P = 0.35 by Kruskal-Wallis). The overall level of Factor IX restoration would be 
sufficient for corrective gene therapy in humans 37,38, thus demonstrating that LTR1 is effective 
as a gene therapy vector in this setting. 
Discussion 
Lentiviruses offer a number of advantages as gene therapy vectors and their development 
continues to progress 3–6. They can be engineered to carry genetic information into a broad range 
of cell types and can efficiently integrate their genomes into target cell chromosomes, resulting 
in permanent DNA delivery. These properties make lentiviral vectors useful in a range of 
scenarios, such as studying the biological effects of transgenes on preclinical disease models, the 
generation of transgenic animal strains and the transfer of therapeutic sequences to treat human 
disease 39,40. Despite these advantages, there is scope for further improvement of lentiviral vector 
technology, given their reported interference with the human genome owing to the concurrent 
delivery of wild-type HIV cis elements 19,41–43. 
We have developed a lentiviral vector with a novel formation that ensures minimal transfer of 
wild-type HIV-1 sequences. The LTR1 reverse-transcription mechanism is unprecedented in 
retrovirology, as all other retroviruses and retrovirus-derived vectors require at least two strand 
transfer events to complete proviral synthesis. In LTR1 vectors, minus strand synthesis is primed 
adjacent to a solitary 3’LTR, thus rendering the usual first strand transfer event obsolete. This 
demonstrates that the first strand transfer event in reverse-transcription is not necessary for 
functional lentiviral transduction of target cells, revealing an interesting facet of HIV biology. 
Importantly, this potentially constitutes a shortening of the viral life-cycle and increased in vivo 
efficacy, analogous to self-complementary AAV (scAAV) 44. 
The structure of the LTR1 provirus reveals interesting insights into HIV biology and brings an 
important technological advancement in terms of the potential safety of clinical gene therapy. 
HIV-1 RNA packaging sequences comprise approximately 1.9kb of its genome, meaning that 3rd 
generation lentiviruses bear 20% sequence homology with wild type HIV-1. Here, and in 
previous studies, lentiviral proviruses have been shown to produce full-length RNA genomes 
that can be remobilised in replicating HIV-1 particles, even with the use of a self-inactivating 
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LTR 22–24. 3rd generation vector genome remobilisation poses a risk that cannot be ignored when 
using standard 3rd generation vectors, but importantly we show that it can be avoided through use 
of LTR1. In our investigations, HIV-1 packaging sequences are undetectable in LTR1 
proviruses, which confer resistance to remobilisation to the limit of detection and provides a 
significant advancement in clinical safety. This is important when considering lentiviral vectors 
as agents for treatment of HIV-1 infections and, as the number of trials using lentiviruses 
increases and becomes more widespread, this will concurrently increase the risk of co-infection 
with HIV. 
HIV-1 packaging sequences contain active splice donor and splice acceptor sites, which have 
previously proven very difficult to remove from vector genomes 27–29. We performed a 
preliminary investigation into the frequency of vector-host fusion transcripts in HEK 293T cells 
transduced with LTR1 and standard lentiviral vectors. Data resulting from these initial analyses 
showed that LTR1 technology can reduce the frequency of splice fusions by 87%, compared to 
standard lentiviral vectors. LTR1.20 fusion transcripts were slightly higher than LTR1.7.671, 
possibly due to the presence of an intron in the LTR1.20 leader sequence, but still showed a 
73.5% reduction from the CCL level. The reduced propensity of LTR1 to splice into cell genes 
would enhance clinical safety by reducing the risk of generating potentially harmful patient-
vector fusion transcripts. This would bring significant advantages for the long-term clinical use 
of lentiviral vectors, given the reported links between retrovirus-host fusion transcripts and 
oncogenesis and warrants further investigation in the future 41,43,45,46. 
We have shown that LTR1 vectors can be produced at titres sufficient for preclinical gene 
therapy. We demonstrated LTR1-mediated correction a haemophilia B mouse model, in which 
LTR1.25 and LTR1.27 were able to deliver liver vector copy numbers equal to a standard CCL 
lentiviral vector. Plasma Factor IX expression was detected at therapeutic levels and with 
sufficient biological activity, upon termination of the experiment, indicating that LTR1 could be 
used for stable disease correction in a gene therapy setting. 
Close analysis showed that LTR1.27 restored mouse plasma Factor IX activity to around 24% of 
normal levels when delivered at a similar dose to CCL, which returned around 13%. The level of 
Factor IX expression derived per injected LTR1.27 genome is an intriguing matter for further 
investigation. Whilst encouraging, it cannot be ignored that all vector doses were based on the 
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infectious titre, which we have identified as being lower than the physical particle titre in the 
case of LTR1.20, compared to CCL. Therefore, there is a possibility that excess defective 
particles were also injected along with functional LTR1.25 and LTR1.27 particles, potentially 
impacting on transduction. Possible mechanisms might include blocking clearance of particles in 
cells such as Kupffer cells, thus allowing more vector particles to infiltrate hepatocytes. 
During longitudinal tracking of luciferase expression in neonatally-injected CD1 mice, LTR1 
showed significantly more liver bioluminescence than a titre-matched 3rd generation CCL over 
the course of the experiment (36 days). The exact mechanism for this difference is unclear, and 
the influence of excess defective particles cannot be ruled out, considering that the CCL profile 
appears to match LTR1 at early stages of the investigation before decreasing from day 18, which 
was less pronounced with LTR1. This profile was not observed following brain transduction. 
An intriguing feature witnessed during LTR1 characterisation was the rapid onset of transgene 
expression. This was observed both in vitro and in vivo, with two separate vector transgene 
cassettes. Following intracerebral and intravenous LTR1.20-luciferase injections, mice were 
immediately examined for bioluminescence. This investigation revealed that LTR1.20 was 
capable of producing luciferase expression 20 minutes after injection, potentially indicating a 
unique functionality that could be exploited. This early level of expression was not provided by 
3rd generation CCL. Leading on from this finding, we sought to investigate how the structure of 
LTR1 RNA could influence the timing of transgene expression in vitro. This experiment 
revealed that when LTR1 was lacking a 5’LTR (LTR1.13.0, Figure 2a), there was a significant 
acceleration of transgene expression during the initial 48 hours after transduction. Again, this 
may relate to the scAAV vector paradigm in which shortening of the replication phase of 
transduction improves the speed and efficiency of transgene expression 44. Given that the 
percentage of eGFP-positive cells increased across every time-point, we would expect that any 
delivery of pseudo-packaged eGFP protein 47 or direct translation of vector RNA 48 would have 
had a negligible effect on total eGFP output. 
The data concerning the onset of reverse-transcription products suggest that the smaller LTR1 
genome and unique reverse-transcription pathway may facilitate rapid copying of its RNA 
genome thus accelerating the onset of gene expression. Interestingly, LTR1.11.1, which does 
perform both strand transfer events, also produced reverse-transcription products earlier than a 
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standard vector, suggesting that minus-strand transfer is not the exclusive reason for differences 
in the speed of transduction. The size of the LTR1.11.1 provirus is approximately 1.5kb smaller 
than that of the standard CCL vector, thus the speed of transduction may be partly influenced by 
the size and complexity of the template to be copied. This rapid onset of expression constitutes a 
unique feature of LTR1 that may be exploited for gene therapy purposes in scenarios requiring 
vector expression within a short time frame. This could be particularly advantageous during ex 
vivo manipulation of stem cells and when using non-integrating lentiviral vectors, given that 
unintegrated proviruses are rapidly lost from dividing cells after repeated passages. 
Our extensive characterisation of LTR1 vectors has revealed interesting features that will be 
important to consider when moving forward with further LTR1 development. During northern 
blot analysis of packaged vector genomes, we discovered that LTR1 vectors are dependent on 
the expression of HIV-1 Tat in producer cells for efficient transcription of full-length viral 
genomes. We observed that shorter transcripts were generated in the absence of Tat, presumably 
due to undesirable termination of transcription and poly-adenylation at the solitary LTR. We 
expect that this was rescued by Tat due to its ability to promote transcriptional read-through of 
the 3’LTR through its binding the HIV-1 trans-activation response element (TAR) 49. 
Additionally, we have highlighted that in vitro transduction of cells requires a greater LTR1.20 
p24 dose and vector RNA dose to match the efficacy of a standard lentiviral vector. LTR1.20 
RNA titres and physical particle titres were calculated as being similar to CCL, suggesting that 
RNA packaging is not compromised. However, the reduced titre of integrated proviruses and 
GFP-forming units suggest that differences may exist in the processing of LTR1.20 RNA during 
transduction and integration. The later generations of LTR1.25 and LTR1.27 show improved 
titres, hinting at an improved level of stable transduction efficiency. As LTR1 technology 
continues to progress, it is possible that the efficiency of transduction will eventually match that 
of standard lentiviral technology. By understanding and controlling LTR1 characteristics, there is 
potential to further increase the infectious titre through experimentation and process 
development to exploit its unique characteristics. Furthermore, if integration efficiency does 
prove to be the limiting factor for in vitro LTR1 efficacy, then LTR1 could be expected to meet 
the efficiency of standard lentiviral technology when used as an integration-deficient lentivirus 
(IDLV). Until the precise mechanism for limited LTR1 infectivity is defined, we must 
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acknowledge the risk that the presence of defective LTR1 particles might create, which could 
theoretically cause adverse effects in humans. Furthermore, a low infectious titre versus physical 
titre could negatively impact on the feasibility of licensed LTR1 products. 
Gene therapy with lentiviral vectors is being pursued for a rapidly increasing cadre of diseases 
including beta globinopathies, chronic granulomatous disease, leukodystrophies and blood 
cancers 50–55. As the range of targets broadens and larger patient populations stand to benefit, it 
will be necessary to ensure that vectors provide the maximum assurance of patient safety. LTR1 
vector technology offers a safety improvement that meets this need and could form an important 
component of next-generation lentiviral vectors. 
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Materials and Methods 
Generation of plasmid constructs 
All plasmid constructs were made using standard molecular cloning procedures and PCR-
mediated deletion of plasmid sequences 56. Detailed plasmid information is available upon 
request. 
Cell culture maintenance 
Human embryonic kidney cell line 293T (HEK 293T) was used for production of viral vectors, 
remobilisation assays and for analysis of fusion transcripts. HT1080, a human 
fibrosarcoma cell line, was used for titration of vector copy numbers by qPCR. HEK 293T and 
HT1080 cell lines were cultured at 37 °C in Dulbecco’s Modified Eagle Medium (DMEM, 
Invitrogen) supplemented with 10% (v/v) fetal bovine serum. All lines were split three times per 
week, when ~80% confluence was reached. 
Production of lentiviral vectors 
Lentiviruses were produced using a second-generation packaging system as described previously 
3. Briefly, 1.8 x 107 HEK 293T cells were plated in a 15cm dish and transfected with 40µg of the 
relevant transfer plasmid, 30µg of pCMVΔR8.74 and 10µg of pMDG.2 DNA (plasmids 
produced by Plasmid Factory) was mixed in 5ml Opti-MEM® and filtered through a 0.22µm 
filter before combining with 5ml Opti-MEM (Lifetech / GE) containing 1µl of 10mM 
polyethylenamine (PEI, Sigma). The resulting 10ml mixture was applied to HEK 293T cells after 
20 minutes incubation at room temperature. The transfection mix was removed after 4 hours and 
replaced with fresh culture medium. Virus-containing medium was collected twice at 48 hours 
and 72 hours post-transfection. After each harvest the collected medium was filtered through a 
cellulose acetate membrane (0.45µm pore). Lentivirus harvests were combined before 
concentration by ultracentrifugation. Briefly, viruses were placed in 25x83mm polyallomer 
centrifuge tubes (Beckman Coulter) and centrifuged for 2 hours at 90000xg at 4°C in a Sorvall 
Discovery 90SE Centrifuge. Following centrifugation the supernatant was removed and the 
pellet was re-suspended in 200µl Opti-MEM for 500-fold concentration. 
Titration of lentiviral vectors 
Page 19 of 36 
 
Vector titration by flow cytometry: 1 x 105 HEK 293T cells were plated into each well of a 6 
well plate and transduced with a range of volumes of concentrated lentivirus. 72 hours after 
transduction, cells were trypsinised and eGFP-positive cells were quantified using a BD Cyan 
flow cytometer or BD FACSArray™ Bioanalyzer 3 days after transduction. 
HEK 293T cells were not used for qPCR titration due to their reported abnormal karyotype 57. 
Briefly, 1 x 105 HT1080 cells were plated into each well of a 6 well plate and transduced with a 
range of volumes of concentrated lentivirus. Seventy-two hours after transduction, genomic 
DNA was extracted and the provirus titre calculated by qPCR, as described previously 58. The 
viral capsid number was determined using a p24 ELISA kit (Clontech - 632200). The capsid 
number was determined according to the kit manufacturer’s calculations, where 1ng p24 is 
equivalent to 1.25 x 107 lentiviral particles (lp). The vector RNA genome titre was determined 
using a qRT-PCR RNA titration kit containing pre-designed primers and standards (Clontech - 
631235). For all titre comparisons, LTR1 and 3rd generation vectors were produced side-by-side 
to account for variations between production batches. 
Detection of eGFP expression in transduced cells 
Flow cytometric detection of eGFP expression was used for titration and characterisation of 
LTR1 vectors. Unless stated otherwise, 100,000 cells were analysed for detection eGFP 
expression in a BD FACSArray™ Bioanalyzer. eGFP fluorescence was excited using a 488nm 
laser. During analysis of flow cytometry plots, cells were gated by plotting forward-light-scatter 
versus side-scatter to isolate the live population. eGFP-positive populations were identified by 
plotting eGFP fluorescence (detected using a 530/30nm band pass filter) versus emission from 
the yellow channel (detected using a 575/26 band pass filter) to compensate for auto-fluorescent 
events. Non-transduced cell populations were used as negative controls to set the background 
level of emission in each channel. All flow cytometry data were analysed by FlowJo software 
version 9.3.1 (Tree Star, Inc). 
Dose-response profiling of LTR1 vectors vs 3rd generation lentiviral vectors in vitro 
HT1080 cells were infected with either LTR1.20-SFFV-Luc-T2A-eGFP or CCL-SFFV-Luc-
T2A-eGFP at a range of MOI, prepared by serial 2-fold dilutions of starting stocks. To avoid the 
influence of unintegrated lentiviral expression, cells were expanded for 14 days before analysis 
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by flow cytometry and genomic DNA extraction for proviral copy number analysis. The starting 
vector stock was assayed for p24 concentration by p24 ELISA and the vector RNA genome titre 
was calculated by qRT-PCR, with methods described in ‘Titration of Lentiviral Vectors’. 
PCR analysis of integrated LTR1 proviruses 
HT1080 cells were transduced with either LTR1.20-SFFV-eGFP or CCL-SFFV-eGFP at an MOI 
of 10. Two weeks after transduction, cells were harvested and genomic DNA was extracted using 
a DNeasy Blood and Tissue kit (Qiagen). To determine the size of the vector backbone, genomic 
DNA was PCR-amplified using oligos specific for the lentiviral 5’LTR-PBS junction (5’-
AAATCTCTAGCAGTGGCGCCCGAACAG-3’) and the 3’LTR R region (5’-
GCACTCAAGGCAAGCTTTATTGAGGCTT-3’) 59. The PCR was carried out using q5 
polymerase (New England Biolabs) with conditions: 98°C for 30 seconds; followed by 28 cycles 
of 98°C for 10 seconds and 72°C for 1 minute 50 seconds; and a final step of 72°C for 2 minutes. 
Amplicons were visualised on a 1% agarose gel to confirm provirus sizes. 
Northern blotting of vector RNA 
RNA species from pCCL, pLTR.1.7.671 and pLTR1.20 were analysed during particle production 
or after proviral integration. For analyzing vector genomes during packaging, 107 HEK 293T 
cells were transfected with 12µg pcDNA3.HIV-1g/p.4xCTE 60, 5µg pRSV.Rev (kindly provided 
by T. J. Hope, Chicago, IL, USA), 5µg pcDNA3.Tat, 2µg pMD2.G and 5µg pCCL, 
pLTR.1.7.671 or pLTR1.20 vector DNA using the calcium phosphate transfection method. 
Transfection was controlled by co-transfecting 2µg non-viral pCMV.DsRedexp expression 
plasmid (Clontech Takara, Saint-Germain-en-Laye, France). Two days post transfection, the 
cells were harvested, analyzed by flow cytometry and their total RNA was extracted using 
RNAzol-RT (Molecular Research Center Inc., Cincinnati, OH, USA) according the 
manufacturer’s instruction. For the analysis of proviral vector RNA species, 2x105 HEK293T 
cells were transduced with serial dilutions of CCL, LTR.1.7.671 or LTR1.20. Four days post 
transduction, cells were harvested, analyzed by flow cytometry and the total RNA of similarly 
transduced cells (59-65% EGFP+) was extracted with RNAzol-RT. All isolated RNAs were 
subjected to northern blot analysis using standard protocol procedures. In brief, 10µg of each 
RNA sample were separated on 1% agarose gel under denaturing conditions, transferred to a 
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Biodyne B membrane (Pall Corporation, Dreieich, Germany) and analyzed via radioactive 
probing. Probes directed against eGFP and 18S RNA (loading control) were labeled with 32P 
using the DecaLabel DNA Labeling Kit (Thermo Fisher Scientific, Waltham, MA, USA). 
Examination of provirus structure by plasmid rescue 
The CCL-Rescue and LTR1.20-Rescue plasmids were produced by excising the pBR322 61 
elements from the respective plasmids and relocating them to the lentiviral transgene region 
(Supplementary Figure S4). HEK 293T cells were plated in 6 well plates at a density of 1 x 105 
cells per well and transduced with either 10µl (0.1µg p24) of concentrated CCL-Rescue or 200µl 
(15µg p24) of concentrated LTR1.20-Rescue. Cells were maintained in culture for 2 weeks 
before extracting genomic DNA. For each sample, 10µg of genomic DNA was treated with XbaI 
(to ensure extensive cutting of the human genome whilst avoiding digestion of viral genomes) 
for 1 hour before column purification (Qiagen PCR Purification Kit - 28104) and ligation. 
Electrocompetent Stbl4 cells (Life Technologies) were transformed with the ligated sample in a 
0.1mm electroporation cuvette at a frequency of 1.2kHz and 25µF capacitance. Transformed 
bacteria were then selected on agar plates (100µg/ml ampicillin) to isolate any provirus-
containing colonies, from which plasmid DNA was harvested and screened for the presence of 
lentiviral proviruses by targeted restriction digest of lentiviral LTRs (with AflII) extracted 
plasmid DNA. The provirus-containing plasmids were subsequently sequenced to determine the 
composition of integrated LTR1.20 and CCL proviruses. 
Detection of remobilised self-inactivating lentiviral genomes 
HEK 293T cells were transduced with CCL-SFFV-eGFP or LTR1.20-SFFV-eGFP with a range 
of vector doses. 11 days after transduction, a sample of each population was taken for genomic 
DNA extraction and qPCR quantification of vector copy numbers. For each production replicate, 
1.8 x 107 transduced cells were seeded into T175 flasks. 24 hours later, each flask was 
transfected with 30µg of pCMVΔR8.74 and 10µg of pMDG.2. DNA was mixed in 5ml Opti-
MEM and filtered through a 0.22µm filter before combining with 5ml Opti-MEM containing 1µl 
PEI (10mM). The resulting 10ml mixture was applied to the transduced cells after 20 minutes 
incubation at room temperature. The transfection mix was removed after 4 hours and replaced 
with fresh culture medium. Lentiviral supernatants were processed as described in ‘Production of 
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Lentiviral Vectors’ section. Fresh HEK 293T cells were seeded in 6 well plates at a density of 1 
x 105 cells per well and transduced with 50µl of the concentrated viruses (n=3). Eleven days after 
transduction, cells were analysed by flow cytometry to detect the number of eGFP-expressing 
cells. Cells were analysed in a BD FACSArray™ Bioanalyzer and non-transduced cells provided 
the baseline for background fluorescence. 
Transcriptomic profiling of vector-host fusion transcripts 
HEK 293T cells were transduced with either CCL-GAPDH-eGFP, LTR1.7.671-GAPDH-eGFP 
or LTR1.20-GAPDH-eGFP at a range of doses and vector copy numbers quantified by qPCR. 
Samples with similarly matched copy numbers were processed for transcriptomic profiling. Total 
RNA was extracted from cells and 1µg was processed, with ribosomal RNA depleted using the 
Kapa Riboerase kit (Kapa Biosystems – KK8483). RNA was fragmented to produce intact 
fragments of 200-300bp and adapter-ligated sequencing libraries were prepared according to the 
manufacturer’s protocol. Libraries were sequenced on the Illumina NextSeq system. Fastq files 
were analysed on the Galaxy platform 62 (usegalaxy.org instance) by mapping paired reads to the 
human genome (hg38) using HISAT 63 and subsequently BWA-MEM 64 mapping the pair of 
hg38-aligned reads to the relevant vector provirus. 
Animal procedures 
For in vivo investigations, outbred CD1 mice (Charles River), or Haemophilia B mice 65 were 
time mated to produce neonatal animals. At postnatal day 1, non-randomised neonates were 
subjected to brief hypothermic anaesthesia and injected with lentiviral vectors via the appropriate 
route. Intracranial injections were performed bilaterally into the lateral ventricles 66. Intravenous 
injections were administered via the superficial temporal vein. Experimental groups were blinded 
during the course of in vivo investigations, with the exception of images taken for Figure 6a. All 
experiments were performed in accordance with relevant guidelines and regulations. 
Experiments were carried out under United Kingdom Home Office regulations and approved by 
the ethical review committee of University College London. 
Confirmation of vector efficacy in vivo by luciferase expression 
Page 23 of 36 
 
To monitor LTR1 bioluminescence in vivo, LTR1.20-SFFV-Luc-T2A-eGFP (2.0 x 107 TU/ml) 
or CCL-SFFV-Luc-T2A-eGFP vectors (3.6 x 107 TU/ml) were administered either intracranially 
(2 x 5µl bilaterally) or intravenously (40µl) to 1-day old neonatal CD-1 mice. Images and 
bioluminescence data were gathered continually for 36 days as described previously 34. Briefly, 
animals were intraperitoneally injected with firefly D-luciferin (150 mg/kg) and imaged after 
5 minutes with a cooled charge-coupled device (CCD) camera (IVIS Lumina II, PerkinElmer). 
Regions of interest were defined manually using a standard area for the organ under 
investigation. Signal intensities were expressed as photons per second per cm2 per steradian, with 
background signal measured at each time-point and subtracted from test values. 
Immunohistochemistry staining and eGFP imaging of LTR1.20-SFFV-eGFP transduced 
brains 
CD-1 mice were injected with LTR1.20-SFFV-GFP (2.34 x 107 TU/ml) at postnatal day 1. Mice 
received vector either by direct intracranially injection into the left lateral ventricle (5µl), or 
intravenously (20µl). One week later they were sacrificed and organs imaging by fluorescence 
microscopy (Leica MZ16) or immunohistochemistry. For immunohistochemistry, brains were 
embedded in paraffin wax and sliced in the coronal plane in preparation for eGFP-staining. Brain 
sections were treated with 30% H2O2 in TBS for 30 minutes and blocked with 15% of goat 
serum (Vector Laboratories, Cambridge, UK) in TBST for 30 minutes. Rabbit anti-GFP 
(1:10000; Abcam, Cambridge, UK) was added in 10% goat serum in TBST and left on a gentle 
shaker overnight at 4°C. Goat anti-rabbit (1:1000; Vector Laboratories) was then added in 10% 
goat serum in TBST for 2 hours. The sections were incubated for a further 2 hours with 
Vectastain ABC (Vector Laboratories), followed by addition of 0.05% 3,3’-diaminobenzidine 
(DAB) and brief incubation. Sections were transferred to ice cold TBS. Each individual brain 
section was mounted on chrome gelatin-coated Superfrost-plus slides (VWR, Poole, UK) and left 
to dry for 24 hours. The slides were dehydrated in 100% ethanol and placed in Histoclear 
(National Diagnostics, Yorkshire, UK) for 5 minutes before mounting with DPX mounting 
medium (VWR). 
Monitoring in vitro eGFP expression during early stages of LTR1 transduction 
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HT1080 cells were plated onto 6 well plates at a density of 1 x 105 cells per well in a 1ml volume 
and simultaneously transduced with either LTR1.11.1-GAPDH-eGFP, LTR1.13.0-GAPDH-
eGFP or CCL-GAPDH-eGFP at an MOI of 1. At various time-points after transduction, cells 
were trypsinsed and harvested for flow cytometric analysis of eGFP expression as described in 
titration methods. Genomic DNA was extracted from cell pellets and analysed for reverse 
transcription products using a previously reported ‘Late RT’ qPCR assay35. Briefly, genomic 
DNA was treated with DpnI restriction enzyme to remove any plasmid carried over during vector 
production, before qPCR analysis by absolute quantification. Copy numbers were extrapolated 
from a standard curve and copy numbers were expressed relative to the copy number detected at 
24 hours post-transduction. 
LTR1-mediated Factor IX delivery 
A codon-optimised version of Factor IX cDNA (FIX) containing the hyperactive Padua mutation 
36 was synthesised by Integrated DNA Technologies and cloned into pLTR1.25-SFFV, 
pLTR1.27-SFFV-FIX or pCCL-SFFV using AgeI and SalI restriction sites. Either CCL-SFFV-
FIX (dose of 1.4 x 107 dsDNAvg/ml) (n=4), LTR1.25-SFFV-FIX (dose of 1.7 x 107 
dsDNAvg/ml) (n=4), or LTR1.27-SFFV-FIX (dose of 1.7 x 107 dsDNAvg/ml) (n=3) was 
intravenously administered to Factor IX-deficient mice at postnatal day 1 (n = 4 each). Blood 
samples were collected by lateral tail-vein puncture upon termination of the experiment (67 days 
for CCL and LTR1.25, 37 days for LTR1.27). Plasma samples were analysed for factor IX 
expression by ELISA (VisuLize Factor IX antigen kit – Affinity Biologicals) and for factor IX 
activity by chromogenic assay (Biophen Factor IX chromogenic assay – Aniara). During the 
investigation, one untreated mouse was culled due to excessive bleeding and one LTR1.25-
treated mouse was culled due to low body weight. 
Statistical analysis 
All statistical analyses were carried out using either Matlab 2015a or Python SciPy open-source 
software 67. Line plots were compared by calculating the area under the curve (AUC) by 
trapezoidal numerical integration and subsequently performing a statistical test on the grouped 
data. For multiple comparisons of eGFP percentage data, the Kruskal-Wallis test was used to 
compare mean AUC, as normal distribution of data was not assumed. For comparison of 
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titrations and bioluminescence, a two-tailed Welch t-test was used to compare mean AUC. Both 
statistical tests employed are robust for datasets without equal variance or sample size. Mouse 
sample sizes were limited to 3 or 4 animals per experimental group for in vivo investigations. 
Polynomial curve fitting for ELISA and chromogenic assays were modeled in Matlab 2015a. 
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Tables 
Vector RNA titre Particle 
titre 
Provirus 
titre 
eGFP titre RT efficiency Expression 
efficiency 
Packaging 
efficiency 
CCL 
1.35E+11 
ssRNAvg/
ml 
1.68E+11 
lp/ml 
2.23E+10 
dsDNAvg
/ml 
1.62E+10 
TU/ml 
33.04 % 72.80 % 80.21 % 
LTR1.20 
2.24E+11 
ssRNAvg/
ml 
2.60E+11 
lp/ml 
1.84E+08 
dsDNAvg
/ml 
1.09E+08 
TU/ml 
0.16 % 58.96 % 86.32 % 
Table 1. ssRNAvg/ml – ssRNA vector genomes per ml; lp/ml –lentiviral particles per ml; 
dsDNAvg/ml – dsDNA vector genome proviruses yielded per ml; TU/ml – eGFP-forming 
transducing units per ml; RT - reverse-transcription. 
Figure legends 
Figure 1. The structure of LTR1 gives rise to RNA and DNA products that are distinct from 
CCL. CCL and LTR1 plasmid genomes (top row) are both driven by a CMV promoter to 
produce ssRNA vector genomic transcripts in producer cells (second row). CCL genomic 
transcripts are flanked by the HIV-1 R region at their extreme termini, whereas LTR1 is 
rearranged, so that the transcript contains a primer binding site (PBS) at its extreme 5’ terminus 
and an additional PBS adjacent to a solitary self-inactivating LTR, with HIV-1 packaging 
sequences (Ψ-RRE – highlighted in red boxes) situated downstream of both PBS sequences. This 
means that reverse-transcription initiates upstream of Ψ–RRE and these sequences are not 
converted into double-stranded DNA. The result is that LTR1 products are devoid of Ψ–RRE 
and are thus smaller than CCL products. 
 
 
Figure 2. Key stages of the LTR1 development process. a. LTR1 genomes were developed based 
on the pRRL-PGK-eGFP (pRRL-PEW) or pCCL-GAPDH-eGFP (pCCL-GEW) 3rd generation 
lentiviral plasmids. pLTR1.0 was made by transferring the pRRL packaging sequences 
downstream of the 3’self-inactivating LTR. pLTR1.5 introduced the ‘late’ SV40 polyA site 
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(SV40LpA) in place of the ‘early’ SV40 polyA site (SV40EpA). pLTR1.7.671 replaced the viral 
RSV promoter with the CMV promoter. pLTR1.11.1 was designed to investigate the influence of 
minus strand exchange, with the 5’LTR components returned to the genome. This was directly 
compared with pLTR1.13.0, which was similar to pLTR1.11.1, but lacked a 5’LTR and had a 
PBS returned to the 3’end, to remove minus strand exchange. pLTR1.20 introduced a 133bp 
chimeric intron to mimic the effects of HIV-1 splice sites. pLTR1.25 and pLTR1.27 were 
designed to further improve titres by examining the influence of the 476bp human beta-globin 
intron and the 939bp human elongation factor 1 alpha (EF1) intron upstream of the GAPDH 
promoter. RSV – Rous-Sarcoma Virus promoter; RU5 – R and U5 components of HIV-1 LTR; 
PBS – HIV-1 primer binding site;  – HIV-1 packaging signal; MSD – HIV-1 major splice 
donor; Gag – truncated and inactive HIV-1 gag gene; RRE – HIV-1 Rev-Response Element; 
cPPT – central polypurine tract; PGK – human phosphoglycerate kinase promoter; eGFP – 
enhanced green fluorescent protein; WPRE – woodchuck-hepatitis virus post-transcriptional 
regulatory element; PPT – polypurine tract; SIN LTR - self-inactivating 3’LTR; DIS – HIV-1 
dimer initiation sequence; GAPDH – human Glyceraldehyde-3-Phosphate Dehydrogenase 
promoter; pCi intron – chimera between introns from human -globin and immunoglobulin 
heavy chain genes;  globin intron - internally truncated intron from human -globin; EF1 
intron – intron upstream of human EF1 start codon. b. Progressive titre increases through 
LTR1 development process. Step-wise optimisation of the LTR1 backbone gradually increased 
the functional titres from 0.04% of standard 3rd generation levels to the current level of 35% (P 
= 0.004 by Kruskal-Wallis comparison of all titres). All titres are based on functional eGFP 
output and LTR1 titrations were performed in parallel with a wild-type 3rd generation vector. 
LTR1 iterations driven by the RSV viral promoter and PGK internal promoter (LTR1.0 and 
LTR1.5) were compared to pRRL-PEW titres, whilst all subsequent LTR1 titres were compared 
to pCCL-GEW. Bars represent mean values with error bars showing standard error of the mean 
mean. 
 
Figure 3. Characterisation of LTR1 vector titres in vitro. a. Plotting the integrated vector copy 
number versus the mean fluorescence intensity (MFI) of eGFP expression in HT1080 cells two 
weeks after transduction shows that expression intensity from transgenes delivered by LTR1.20-
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SFFV-Luc-T2A-eGFP (red lines, cross markers) or a 3rd generation CCL vector (blue lines, 
circular markers) are equivalent per integrated provirus. b. When comparing the percentage of 
GFP positive cells versus the vector dose according to gag p24 mass, it becomes apparent that 
LTR1.20 vectors require a higher particle dose to match the CCL level of efficacy in vitro. c. 
Further to this, when plotting the level of GFP positive cells versus the total vector dose in terms 
of RNA genomes, we see that a greater number of LTR1 genomes are required to match the CCL 
level of transduction. 
 
Figure 4. Analysing the safety parameters of CCL and LTR1 vector proviruses. a. HEK 293T 
cells transduced with CCL-SFFV-eGFP vector proviruses produce a remobilised titre that 
increases in correlation with the number of proviral copies per cell. LTR1.20-SFFV-eGFP 
proviruses do not produce any detectable remobilised genomes at any dose (n = 3 vector 
titrations for each VCN dose; data are expressed as mean transducing units per ml (TU/ml) ± 
s.e.m; P = 0.0004 following t-test comparison of area under the curves). b. Chimeric vector-
human fusion transcripts occur less frequently in LTR1 samples compared to standard lentivirus 
samples. Transcriptomic profiling of HEK 293T cells transduced with either CCL-GEW (n=3), 
LTR1.7.671-GEW (n=3) or LTR1.20-GEW (n=3) was investigated to assess the influence of -
RRE removal from LTR1 proviruses. The number of fusion transcripts detected in CCL samples 
per 106 human genomic transcripts per integrated provirus was significantly greater than those of 
LTR1.7.671 and LTR1.20 (P = 0.027 by Kruskal-Wallis test). c. Expressing the data values 
relative to the CCL fusion transcript frequency shows that LTR1.7.671 (12.97±5.64 % of CCL) 
and LTR1.20 (26.5±0.86 % of CCL) generate chimeric transcripts at a significantly lower rate 
than CCL (P = 0.024 by Kruskal-Wallis test). 
 
Figure 5. LTR1 vectors can be used for efficient in vivo gene delivery. a. Newborn mice were 
either intracranially or intravenously injected with integration-proficient (IPLV) LTR1.20-SFFV-
eGFP to target brain and liver, respectively. After 1 week, macro fluorescence microscopy 
revealed strong eGFP expression in both organs. b. Immunohistochemical staining of paraffin-
embedded coronal slices of injected brains shows neuronal eGFP expression following 
intracranial LTR1 delivery. Black arrows show areas with eGFP positivity, whilst yellow and red 
arrows show hippocampal and cortex staining, respectively. c. Longitudinal bioluminescent 
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monitoring of LTR1 and CCL luciferase expression in the brain. Newborn mice were 
intracranially injected at postnatal day 1 with either CCL-SFFV-Luc-T2A-eGFP or LTR1.20-
SFFV-Luc-T2A-eGFP (n = 3 animals for each group, data expressed as means ± s.e.m). Brain 
bioluminescence was quantified at regular time intervals over a 36 day period. No statistically-
significant difference was detected by t-test (P = 0.087), indicating that LTR1.20 is capable of 
matching standard lentiviral vector brain transduction. d. Bioluminescent monitoring of LTR1 
expression in the liver following intravenous vector injection at postnatal day 1 with either CCL-
SFFV-Luc-T2A-eGFP or LTR1.20-SFFV-Luc-T2A-eGFP (n = 3 animals for each group, data 
expressed as means ± s.e.m). Bioluminescent measured in LTR1.20-transduced livers was 
significantly higher than CCL-transduced livers over the entire 36 day period following t-test 
comparison of area under the curves (P = 0.018). 
 
Figure 6. LTR1 vectors produce transgene expression earlier than standard lentiviruses. a. 
Newborn mice were imaged 20 minutes after intracranial or intravenous injection of CCL-SFFV-
T2A-eGFP or LTR1.20-SFFV-T2A-eGFP, to determine whether any early expression was 
detectable. LTR1 vectors are capable of producing very early transgene expression, which is not 
seen with 3rd generation CCL. b. Time-course experiment showing the timing of eGFP 
expression during the initial 48 hours after transduction. HT1080 cells were plated and 
simultaneously transduced with CCL-GEW (blue line, circle marker), LTR1.11.1-GEW (red 
line, cross marker), or LTR1.13.0-GEW (black line, triangle marker) at MOI 1 (n = 3 for each 
group, data expressed as means ± s.e.m). Transduced cells were harvested at various time-points 
and processed in a flow cytometer to determine the percentage of eGFP-positive cells. The 
LTR1.13.0 vector, which does not contain a 5’LTR, began to produce eGFP expression at an 
earlier time-point and sustained higher expression than CCL or LTR1.11.1 vectors, which do 
contain a 5’LTR. P = 0.039 by Kruskal-Wallis multiple comparison of area under the curves for 
the 3 experimental groups. c. Analysis of reverse-transcription products in HT1080 cells during 
the initial 24 hours post-transduction shows that LTR1.13.0 and LTR1.11.1 products appear 
sooner than those of CCL. Reverse-transcription products are expressed relative to the final copy 
numbers detected at 24 hours post-transduction. 
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Figure 7. LTR1 increases plasma Factor IX expression following treatment of a FIX-deficient 
mouse model. LTR1.25-SFFV-FIX (n = 3), LTR1.27-SFFV-FIX (n=3) or CCL-SFFV-FIX (n = 
4) was intravenously administered to newborn mice and compared to untreated knockouts (n = 
3). Plasma Factor IX was assayed when the experiment was terminated. All data are presented as 
individual data points with overlaid boxplots representing median lines (red), the upper and 
lower range (black lines) and 75% confidence intervals (blue boxes). a. qPCR calculation of liver 
proviral copy numbers found that LTR1.25, LTR1.27 and CCL liver transduction was 
comparable. b. Plasma Factor IX protein levels (% normal levels) and c. plasma Factor IX 
activity levels (% normal levels) were restored to therapeutic levels by all vector treatment 
groups. 
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Supplementary Figure S1. LTR1 reverse-transcription requires fewer intermediate steps than 
a standard lentiviral vector. For all images, grey lines represent RNA, black lines represent 
the DNA product of reverse-transcription, and dashed grey lines represent RNA degraded by 
RNAse H. Left panel. Conventional lentiviral reverse-transcription can be broken-down in 
intermediate steps. A tRNA primer binds to the HIV-1 primer-binding site (PBS) on vector 
RNA and initiates minus strong-stop DNA synthesis, producing single-stranded DNA 
(ssDNA) complementary to the R-U5 portion of the HIV-1 LTR. Vector RNA is concurrently 
degraded by RNAse H, thus leaving R-U5 ssDNA free to base pair with the complementary 
R domain at the 3’ end of the vector RNA. Reverse transcriptase proceeds to complete 
synthesis of minus strand DNA, with PBS at the 5’terminus. Plus strand synthesis is then 
primed from the polypurine tract (PPT), reading through the 3’LTR (U3-R) and the tRNA, 
which is complementary to PBS. A single-stranded PBS is now present at both ends, which 
permits the second strand-transfer event. Reverse transcriptase then proceeds to complete 
plus strand synthesis to produce a double-stranded provirus. Right panel. LTR1 reverse-
transcription operates with fewer intermediate steps than standard lentiviruses. LTR1 vectors 
lack a 5’LTR, so reverse-transcription is primed on an internal PBS downstream of a solitary 
HIV-1 LTR (U3-R-U5 domains). This means that reverse-transcriptase can complete minus 
strand synthesis without performing a strand transfer event and skip straight to minus strand 
extension. Like conventional reverse-transcription, plus strand synthesis is primed from the 
PPT, reading through the full-length 3’LTR and tRNA, which is complementary to the PBS. 
Reading through the tRNA primer displaces the untranscribed RNA at the extreme 3’ end. 
This process displaces the internal PBS and excludes the HIV-1 packaging sequences from 
reverse-transcription. As per conventional reverse-transcription, a single-stranded PBS is now 
present at both DNA termini, which permits the second strand-transfer event and synthesis of 
a double-stranded DNA provirus. With Ψ-RRE sequences situated downstream of all reverse-
transcription events, these sequences are not incorporated into the final LTR1 provirus. 
 
 
  
 Supplementary Figure S2. Northern blot analysis of LTR1 RNA products. HEK293T cells 
were transfected with LTR1.7.671-GEW, LTR1.20-GEW or CCL-GEW plasmids. Vectors 
were produced with or without pcDNA3.Tat during production. RNA was extracted from 
each treated cell population and processed for northern blot, where RNA was probed for 
EGFP. EGFP-probed phosphorescence was exposed for 1 hour (left panel) or 2 hours (right 
panel) at -80°C. Samples were loaded with mass of 10µg, with LTR1.7.671-GEW also loaded 
at 15µg. Red arrow points to the LTR1.7.671-GEW band assumed to be full-length vector 
genome transcript. The mock RNA sample was extracted from untreated HEK 293T cells. 
 
 Supplementary Figure S3. PCR amplification of LTR1.20-SFFV-eGFP provirus. Genomic 
DNA of HT1080 cells transduced with either CCL-SFFV-eGFP (lane 3) or LTR1.20-SFFV-
eGFP (lane 4) was amplified using primers directed against the flanking lentiviral LTRs. 
Water (lane 1) and untransduced HT1080 genomic DNA (lane 2) were devoid of any non-
specific amplification. PCR products were analysed alongside the Invitrogen 10kb+ DNA 
ladder (lane 5), which showed that CCL (3.5kb) and LTR1.20 (2.3kb) samples produced 
amplicons of the expected sizes. The primer binding sites relative to each provirus have been 
shown above the gel image. 
  
  
 
Supplementary Figure S4. Plasmid rescue vector genomes. The pBR322 selection marker, 
containing an ampicillin resistance gene and bacterial origin of replication, was cloned into 
the vector transgene region of pCCL (top) or pLTR.20 (bottom). AmpR – ampicillin 
resistance gene for bacterial selection; Ori – pBR322 plasmid origin of replication for 
propagation in bacterial cells. 
	RSV RU5 PBS Ψ MSD ΔGag RRE cPPT PGK EGFP WPRE PPT SIN LTR SV40EpA 
CMV RU5 PBS Ψ MSD ΔGag RRE cPPT AmpR Ori PPT SIN LTR SV40EpA 
RSV PBS Ψ MSD ΔGag RRE cPPT PGK EGFP WPRE PPT SIN LTR SV40LpA PBS 
CMV PBS Ψ MSD ΔGag RRE cPPT EGFP WPRE PPT SIN LTR SV40LpA PBS 
CMV PBS Ψ MSD ΔGag RRE cPPT EGFP WPRE PPT SIN LTR SV40LpA DIS 
CMV PBS Ψ MSD ΔGag RRE cPPT EGFP WPRE PPT SIN LTR SV40LpA PBS 
CMV PBS Ψ MSD ΔGag RRE cPPT AmpR Ori PPT SIN LTR SV40LpA PBS 
CMV PBS Ψ MSD ΔGag RRE cPPT EGFP WPRE PPT SIN LTR SV40LpA PBS 
RU5 MSD 
DIS MSD 
pCi INTRON 
β globin INTRON 
GAPDH 
 
GAPDH 
 
GAPDH 
 
GAPDH 
 
CMV PBS Ψ MSD ΔGag RRE cPPT AmpR Ori PPT SIN LTR SV40LpA PBS pCi INTRON 
  
CTTCCCCCTTACCTGACAGCTGTTATTAGATTACGGCCGAATGTCCAATCTTTAACATCATGATGTAGG
GCTCTGTGGTTAACCCATTGCCAAATGTTTTATTATTTCCATAGGTTTAGTGGTCCCAACTTCGGATCTC
ATGTGAGGAAGGTCAAAATGACAGCTTGAAAATATTCCTAACCCGGGGATTGCAGTGCCCATAAGAAAT
GATTGCCAGTGGGGAGAAAGCCCATTTGCTGATTCCACATCTTGTGCTAGCTTTTACACAAATCATCTC
ACAGAAGAATTGGAAGGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCT
CTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCA
ATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATC
CCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTGCTAGCCTGG
GCAGGTGTCCACTCCCAGTTCGCTAGCGTTAACTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTG
CAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAA
AAATTCAAAATTTTATCGATCACGAGACTAGCCTCGAGCCAGGTGGCACTTTTCGGGGAAATGTGCGC
GGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATA
AATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTT
TTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGAT
CAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCG
CCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTAT
TGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCAC
CAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATG
AGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTT
GCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAA
ACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAA
CTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTT
CTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTC
GCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGG
AGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTG
GTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGA
TCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGC
GTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTT
GCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCC
GAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCC
ACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTG
CCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCG
GTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGA
TACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGG
TAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTA
TAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGA
GCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACA
TGTGAATTCGAGCTCGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT
AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTA
CTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTT
AAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAAC
TAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAAGAATCCTTACACTCTCTGATGC
AGGAGACAATATCCCCAATCACAGGTGAGGGTGCTGACATTAGAGAAGCAAGCCATTCAGCAACAGCT
TAGGGGAAGAGCTCTCAAATGTAGTGTTTTCATACTCCAAAGTTCAGAGGAAGTGTTTCTTTCCCTTAAA
ATGGCAGCAGTTTTCAATTCTGATGTTATAGCTCAGAAGTGGGGACAGAGAGGGATAGTAGAAGGCTG
CCAAATGACATTAAATGAATTTTTTTCATGACAAAGTAATTCCTCAGAATCAGTTTTTTTCCCATTACCTA
ATTGAAGTATCATTATATTCTCATGTTTAATATGTTATTTAGCATATCACCAAGCAGATTGAAAAGGCCG
AAAATGAGCAAAAGAATGCACATATCACTCACTCATTGCCTGTCTTTGCTCTCTCCCTCATGAAGACATA
GAAGAGGAGGCTAGGGGATGCCCCCTCCTCTTCCCTCAGACAGGGGATTCTCACTGACAGAAATATGT
AATTCTTCACATTGCTTTAAAAATGTTCTTCTTCATGTGTATTTATGTGTTTTCAGCTTACTACTCTTATAC
CACCTGCTGTTCAAACAAAAAATCCCACCAAGCCAAGCAGAATTGATGAATATCCATTTACTTTTATTTT
AAAGGGTGCCTCAACTCTTTCAAATCCTAAAATCTTTACCGTATTAATTTGTTAAGGCTTCCTTTAGTAA
GTCAGGGTAAACCCTAA 
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Supplementary Figure S5. Sequence composition of representative plasmid rescue clone. The 
sequencing data for the rescued LTR1.20 provirus confirms the expected internal provirus 
structure that would be produced following pCi intron splicing in producer cells (non-shaded 
text) and shows the repeated dinucleotide pairs at either end of the integrated provirus (bold 
text) resulting from genomic integration. The shaded text is homologous to human 
chromosome 2, flanking the repeated dinucleotides at position 200238350-200238354. The 
map represents the contents and structure of the provirus, devoid of HIV-1 packaging 
sequences. 
  
 Supplementary Figure S6. Flow cytometry dot plots for remobilisation assay samples. HEK 
293T cells transducd with mock remobilised vectors were analysed by flow cytometry for 
GFP positivity. Vector remobilised by a CCL sample of VCN 2.03 gave clear remobilised 
GFP vector titres, whilst LTR1.20 showed resistance to remobilisation even a higher VCN 
dose of 3.75. 
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 Supplementary Figure S7. Representative bioluminescent images of SFFV-Luc-T2A-eGFP-
transduced animals. Outbred CD1 mice received titre-matched intravenous doses of either 
LTR1.20-SFFV-Luc-T2A-eGFP or CCL-SFFV-Luc-T2A-eGFP at postnatal day 1. Mice 
were imaged continually throughout the following 36 days to track vector expression in vivo. 
Here, we show representative images taken at 20mins (day 0), 5 days, 15 days and 36 days 
post-administration. 
 
